2078 related articles for article (PubMed ID: 19425079)
1. Intrajejunal levodopa infusion in Parkinson's disease: a pilot multicenter study of effects on nonmotor symptoms and quality of life.
Honig H; Antonini A; Martinez-Martin P; Forgacs I; Faye GC; Fox T; Fox K; Mancini F; Canesi M; Odin P; Chaudhuri KR
Mov Disord; 2009 Jul; 24(10):1468-74. PubMed ID: 19425079
[TBL] [Abstract][Full Text] [Related]
2. Intrajejunal levodopa infusion in advanced Parkinson's disease: long-term effects on motor and non-motor symptoms and impact on patient's and caregiver's quality of life.
Fasano A; Ricciardi L; Lena F; Bentivoglio AR; Modugno N
Eur Rev Med Pharmacol Sci; 2012 Jan; 16(1):79-89. PubMed ID: 22338551
[TBL] [Abstract][Full Text] [Related]
3. Eighteen month study of continuous intraduodenal levodopa infusion in patients with advanced Parkinson's disease: impact on control of fluctuations and quality of life.
Puente V; De Fabregues O; Oliveras C; Ribera G; Pont-Sunyer C; Vivanco R; Cucurella G; Giralt E; Delgado T; Garcia C; Seoane A; Campo R
Parkinsonism Relat Disord; 2010 Mar; 16(3):218-21. PubMed ID: 19762271
[TBL] [Abstract][Full Text] [Related]
4. Duodenal levodopa infusion improves quality of life in advanced Parkinson's disease.
Antonini A; Mancini F; Canesi M; Zangaglia R; Isaias IU; Manfredi L; Pacchetti C; Zibetti M; Natuzzi F; Lopiano L; Nappi G; Pezzoli G
Neurodegener Dis; 2008; 5(3-4):244-6. PubMed ID: 18322402
[TBL] [Abstract][Full Text] [Related]
5. Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease.
Nyholm D; Nilsson Remahl AI; Dizdar N; Constantinescu R; Holmberg B; Jansson R; Aquilonius SM; Askmark H
Neurology; 2005 Jan; 64(2):216-23. PubMed ID: 15668416
[TBL] [Abstract][Full Text] [Related]
6. Duodenal levodopa infusion for advanced Parkinson's disease: 12-month treatment outcome.
Antonini A; Isaias IU; Canesi M; Zibetti M; Mancini F; Manfredi L; Dal Fante M; Lopiano L; Pezzoli G
Mov Disord; 2007 Jun; 22(8):1145-9. PubMed ID: 17661426
[TBL] [Abstract][Full Text] [Related]
7. Long-term effect of initiating pramipexole vs levodopa in early Parkinson disease.
Parkinson Study Group CALM Cohort Investigators
Arch Neurol; 2009 May; 66(5):563-70. PubMed ID: 19433655
[TBL] [Abstract][Full Text] [Related]
8. [Rasagiline in daily clinical use. Results of a treatment study of Parkinson patients with a combination treatment].
Jost WH; Klasser M; Reichmann H
Fortschr Neurol Psychiatr; 2008 Oct; 76(10):594-9. PubMed ID: 18833504
[TBL] [Abstract][Full Text] [Related]
9. International study on the psychometric attributes of the non-motor symptoms scale in Parkinson disease.
Martinez-Martin P; Rodriguez-Blazquez C; Abe K; Bhattacharyya KB; Bloem BR; Carod-Artal FJ; Prakash R; Esselink RA; Falup-Pecurariu C; Gallardo M; Mir P; Naidu Y; Nicoletti A; Sethi K; Tsuboi Y; van Hilten JJ; Visser M; Zappia M; Chaudhuri KR
Neurology; 2009 Nov; 73(19):1584-91. PubMed ID: 19901251
[TBL] [Abstract][Full Text] [Related]
10. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial.
Holloway RG; Shoulson I; Fahn S; Kieburtz K; Lang A; Marek K; McDermott M; Seibyl J; Weiner W; Musch B; Kamp C; Welsh M; Shinaman A; Pahwa R; Barclay L; Hubble J; LeWitt P; Miyasaki J; Suchowersky O; Stacy M; Russell DS; Ford B; Hammerstad J; Riley D; Standaert D; Wooten F; Factor S; Jankovic J; Atassi F; Kurlan R; Panisset M; Rajput A; Rodnitzky R; Shults C; Petsinger G; Waters C; Pfeiffer R; Biglan K; Borchert L; Montgomery A; Sutherland L; Weeks C; DeAngelis M; Sime E; Wood S; Pantella C; Harrigan M; Fussell B; Dillon S; Alexander-Brown B; Rainey P; Tennis M; Rost-Ruffner E; Brown D; Evans S; Berry D; Hall J; Shirley T; Dobson J; Fontaine D; Pfeiffer B; Brocht A; Bennett S; Daigneault S; Hodgeman K; O'Connell C; Ross T; Richard K; Watts A;
Arch Neurol; 2004 Jul; 61(7):1044-53. PubMed ID: 15262734
[TBL] [Abstract][Full Text] [Related]
11. EuroInf: a multicenter comparative observational study of apomorphine and levodopa infusion in Parkinson's disease.
Martinez-Martin P; Reddy P; Katzenschlager R; Antonini A; Todorova A; Odin P; Henriksen T; Martin A; Calandrella D; Rizos A; Bryndum N; Glad A; Dafsari HS; Timmermann L; Ebersbach G; Kramberger MG; Samuel M; Wenzel K; Tomantschger V; Storch A; Reichmann H; Pirtosek Z; Trost M; Svenningsson P; Palhagen S; Volkmann J; Chaudhuri KR
Mov Disord; 2015 Apr; 30(4):510-6. PubMed ID: 25382161
[TBL] [Abstract][Full Text] [Related]
12. [Continuous dopaminergic stimulation by Duodopa in advanced Parkinson's disease: Efficacy and safety].
Annic A; Devos D; Seguy D; Dujardin K; Destée A; Defebvre L
Rev Neurol (Paris); 2009; 165(8-9):718-27. PubMed ID: 19150100
[TBL] [Abstract][Full Text] [Related]
13. Quality of life in early Parkinson's disease: impact of dyskinesias and motor fluctuations.
Marras C; Lang A; Krahn M; Tomlinson G; Naglie G;
Mov Disord; 2004 Jan; 19(1):22-8. PubMed ID: 14743356
[TBL] [Abstract][Full Text] [Related]
14. Concurrent administration of donepezil HCl and levodopa/carbidopa in patients with Parkinson's disease: assessment of pharmacokinetic changes and safety following multiple oral doses.
Okereke CS; Kirby L; Kumar D; Cullen EI; Pratt RD; Hahne WA
Br J Clin Pharmacol; 2004 Nov; 58 Suppl 1(Suppl 1):41-9. PubMed ID: 15496222
[TBL] [Abstract][Full Text] [Related]
15. Global long-term study on motor and non-motor symptoms and safety of levodopa-carbidopa intestinal gel in routine care of advanced Parkinson's disease patients; 12-month interim outcomes.
Antonini A; Yegin A; Preda C; Bergmann L; Poewe W;
Parkinsonism Relat Disord; 2015 Mar; 21(3):231-5. PubMed ID: 25585993
[TBL] [Abstract][Full Text] [Related]
16. Effect of duodenal levodopa infusion on blood pressure and sweating.
Pursiainen V; Lyytinen J; Pekkonen E
Acta Neurol Scand; 2012 Oct; 126(4):e20-4. PubMed ID: 22329867
[TBL] [Abstract][Full Text] [Related]
17. Intrajejunal levodopa versus conventional therapy in Parkinson disease: motor and nonmotor effects.
Reddy P; Martinez-Martin P; Rizos A; Martin A; Faye GC; Forgacs I; Odin P; Antonini A; Chaudhuri KR
Clin Neuropharmacol; 2012; 35(5):205-7. PubMed ID: 22821063
[TBL] [Abstract][Full Text] [Related]
18. Patient-perceived involvement and satisfaction in Parkinson's disease: effect on therapy decisions and quality of life.
Grosset KA; Grosset DG
Mov Disord; 2005 May; 20(5):616-9. PubMed ID: 15719417
[TBL] [Abstract][Full Text] [Related]
19. Nonmotor symptoms in de novo Parkinson disease before and after dopaminergic treatment.
Kim HJ; Park SY; Cho YJ; Hong KS; Cho JY; Seo SY; Lee DH; Jeon BS
J Neurol Sci; 2009 Dec; 287(1-2):200-4. PubMed ID: 19700173
[TBL] [Abstract][Full Text] [Related]
20. Influence of motor symptoms upon the quality of life of patients with Parkinson's disease.
Gómez-Esteban JC; Zarranz JJ; Lezcano E; Tijero B; Luna A; Velasco F; Rouco I; Garamendi I
Eur Neurol; 2007; 57(3):161-5. PubMed ID: 17213723
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]